Test Price
6,000 AEDโ Home Collection Available
Preimplantation Genetic Diagnosis for Single Gene Disorders (Known Mutation) โ Baseline in Dubai, UAE | 6,000 AED | DHA Licensed
Executive Summary & Core Metrics
โ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified Sanger Sequencing for known familial mutations.
โ Logistics: Hospital extraction only โ sample collection is conducted strictly within an accredited IVF facility; mobile home phlebotomy is disabled for safety.
โ Clinical Guidance: Complimentary telephonic post-test genetic counselling with a DHA-licensed consultant medical geneticist.
โ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Preimplantation Genetic Diagnosis for Single Gene Disorders (PGD-M) is a targeted diagnostic assay performed on embryos created through in vitro fertilisation (IVF) to detect a specific familial mutation prior to implantation. This baseline PGD-M utilises Sanger Sequencing, the gold-standard method for definitive variant confirmation when the familial mutation is already characterised. The test delivers unambiguous results within 15โ20 working days, enabling reproductive medicine specialists to select unaffected embryos for transfer. The procedure requires a prior known pathogenic mutation identified in the family through parental and affected-child confirmatory testing.
| Feature | Our Test (PGD-M Baseline) | Closest Alternative (NGS-Based PGD) |
|---|---|---|
| Precision | Single-mutation resolution, >99.9% analytical sensitivity for the known variant | Multi-gene screening, ~99.5% sensitivity but requires parental haplotyping and bioinformatic filtering |
| Method | Sanger Sequencing โ international reference standard for targeted variant confirmation | Next-Generation Sequencing panel โ covers multiple loci but carries higher allele dropout risk |
| Turnaround | 15โ20 working days from embryo biopsy receipt | 21โ28 working days including bioinformatic alignment and interpretation |
Physician Insight & Safety Protocols
"Preimplantation genetic diagnosis for known monogenic mutations offers families a powerful opportunity to prevent transmission of serious hereditary disorders. The baseline Sanger sequencing approach provides definitive variant identification when the familial mutation has already been established. I strongly recommend that all couples pursuing PGD-M engage with a multidisciplinary team spanning genetic counselling and reproductive medicine to address the technical, emotional, and ethical dimensions thoroughly every result is a foundation for shared decision-making, never a standalone conclusion."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Clinical Advisory
Patients must continue all prescribed treatments and medications as directed by their managing physician. This diagnostic service is designed to inform reproductive decision-making and should not replace ongoing medical supervision or emergency care. Do not alter or discontinue any therapy based solely on test results without consulting your healthcare provider.
Exclusion Criteria & Urgent Clinical Indicators
- Confirmed intrauterine pregnancy or ongoing clinical pregnancy.
- No known pathogenic mutation previously identified in the family lineage.
- Patient medically unfit or unwilling to undergo ovarian stimulation and IVF/ICSI.
- Emergency Red Flag: Seek immediate medical attention if you develop severe abdominal bloating, rapid weight gain, nausea, vomiting, or dyspnoea following ovarian stimulation โ these may indicate Ovarian Hyperstimulation Syndrome (OHSS).
Patient FAQ & Clinical Guidance
1. What is the accuracy of this baseline PGD-M test for single gene disorders?
A: The test delivers over 99.9% analytical sensitivity for the targeted known mutation when performed on a single cell biopsy from an IVF embryo. It cannot eliminate all genetic risks across the entire genome, and results should always be correlated with confirmatory testing and genetic counselling.
2. Why are blood samples from both parents and an affected child required for baseline testing?
A: Parental and affected-child specimens allow the laboratory to confirm the exact familial pathogenic variant and establish the phase of linked markers used to track the mutation across embryos. Without this trio analysis, definitive single-mutation assignment is not achievable.
3. Is a doctorโs prescription mandatory for this test?
A: Yes, a valid prescription from a DHA-licensed gynaecologist, reproductive endocrinologist, or clinical geneticist is required. This test is specifically indicated for couples with a known monogenic disorder seeking preimplantation genetic testing and is not applicable for general fertility screening or pregnancy confirmation.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genetic and clinical data are processed under strict data protection principles including lawful collection, purpose limitation, data minimisation, and individual rights of access and erasure.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Electronic health records, genetic test results, and IVF cycle data are transmitted and stored in compliance with UAE health ICT security standards with audit trails and encrypted channels.
Federal Decree-Law No. 4 of 2016 on Medical Liability: Clinical testing, patient consent protocols, and reporting obligations adhere to UAE medical liability legislation, ensuring patient safety and professional accountability throughout the diagnostic pathway.
Clinical & Logistical Metadata
| Test Name | Preimplantation Genetic Diagnosis for Single Gene Disorders (Known Mutation) โ Baseline |
| Price (AED) | 6,000 AED |
| Turnaround Time | 15โ20 working days |
| Sample Type / Matrix | Embryo Biopsy (Hospital Extraction Only โ sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety) |
| Methodology Used | Sanger Sequencing |
| ICD-10-CM Code | Z31.48 |
| LOINC Code | 81317-1 |
| DHA Facility License & Laboratory Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DHA License No. 1143 |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians